HUP0104794A2 - Eljárás vírusrészecskék elkülönítésére - Google Patents

Eljárás vírusrészecskék elkülönítésére

Info

Publication number
HUP0104794A2
HUP0104794A2 HU0104794A HUP0104794A HUP0104794A2 HU P0104794 A2 HUP0104794 A2 HU P0104794A2 HU 0104794 A HU0104794 A HU 0104794A HU P0104794 A HUP0104794 A HU P0104794A HU P0104794 A2 HUP0104794 A2 HU P0104794A2
Authority
HU
Hungary
Prior art keywords
viral particles
separating viral
separating
sadenoviruses
fringed
Prior art date
Application number
HU0104794A
Other languages
English (en)
Inventor
Anne Barbot
Francis Blanche
Béatrice Cameron
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9816737A external-priority patent/FR2788064B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0104794A2 publication Critical patent/HUP0104794A2/hu
Publication of HUP0104794A3 publication Critical patent/HUP0104794A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A tal lm ny t rgya egy új elj r s vírusrészecskéknek biológiaik"zegből kiinduló elkül"nítésére és mennyiségi meghat roz s ra. Az eljr s legal bb egy kromatogr fi s lépést tartalmaz, ebben olyan hordozótalkalmaznak, amely egy m trixot és arra flexibilis oldall ncokkal rojtott ioncserélő csoportokat tartalmaz. A tal lm ny szerinti elj r sadenovírusok kül"nb"ző szerotípusainak azonosít s ra is alkalmazható. Ó
HU0104794A 1998-12-31 1999-12-30 Method for separating viral particles HUP0104794A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9816737A FR2788064B1 (fr) 1998-12-31 1998-12-31 Methode de separation de particules virales
US11994899P 1999-02-12 1999-02-12
PCT/FR1999/003315 WO2000040702A1 (fr) 1998-12-31 1999-12-30 Methode de separation de particules virales

Publications (2)

Publication Number Publication Date
HUP0104794A2 true HUP0104794A2 (hu) 2002-04-29
HUP0104794A3 HUP0104794A3 (en) 2006-03-28

Family

ID=26234748

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104794A HUP0104794A3 (en) 1998-12-31 1999-12-30 Method for separating viral particles

Country Status (15)

Country Link
US (2) US6537793B2 (hu)
EP (1) EP1141249A1 (hu)
JP (1) JP2003523169A (hu)
KR (1) KR100762033B1 (hu)
CN (1) CN1195057C (hu)
AU (1) AU779267B2 (hu)
BR (1) BR9916654A (hu)
CA (1) CA2356373A1 (hu)
CZ (1) CZ20012428A3 (hu)
HU (1) HUP0104794A3 (hu)
IL (2) IL143381A0 (hu)
NO (1) NO20013271L (hu)
NZ (1) NZ512504A (hu)
PL (1) PL349074A1 (hu)
WO (1) WO2000040702A1 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU756889B2 (en) 1998-04-22 2003-01-23 Genvec, Inc. Efficient purification of adenovirus
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CZ20012428A3 (cs) * 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
SI2277996T1 (sl) 2003-05-21 2014-12-31 Genzyme Corporation Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid
CN1816619A (zh) * 2003-06-18 2006-08-09 昂尼克斯药物公司 纯化病毒的方法
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
RU2411081C2 (ru) * 2005-07-06 2011-02-10 Джи-И Хелткер Байо-Сайенсиз АБ Способ изготовления разделяющей матрицы
GB0515577D0 (en) * 2005-07-29 2005-09-07 Amersham Biosciences Ab Process for cross-linking cellulose ester membranes
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
KR100813268B1 (ko) * 2006-09-25 2008-03-13 삼성전자주식회사 이온교환반응 및 미생물 포획 수단을 이용하여 시료로부터미생물을 분리하는 방법, 미생물 시료의 전처리용 용기 및미생물분리 장치
EP2066418A4 (en) * 2006-09-29 2011-12-28 Ge Healthcare Bio Sciences Ab SEPARATION MATRIX FOR VIRAL PURIFICATION
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
ES2586613T3 (es) * 2007-05-04 2016-10-17 Bio-Works Technologies Ab Método para la fabricación de geles de agarosa
ES2532015T3 (es) * 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
CN102575233B (zh) * 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
WO2011086509A1 (en) * 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
JP2013523175A (ja) * 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
KR102196230B1 (ko) 2012-09-17 2020-12-29 더블유.알. 그레이스 앤드 캄파니-콘. 크로마토그래피 매질 및 장치
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
CN107847907A (zh) 2014-05-02 2018-03-27 格雷斯公司 官能化载体材料以及制备和使用官能化载体材料的方法
JP6652554B2 (ja) 2014-09-02 2020-02-26 イー・エム・デイー・ミリポア・コーポレイシヨン ナノフィブリル化表面特徴を有する高表面積繊維媒体
KR102162753B1 (ko) 2014-12-08 2020-10-07 이엠디 밀리포어 코포레이션 혼합층 이온 교환 흡착제
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR102566292B1 (ko) 2015-06-05 2023-08-10 더블유.알. 그레이스 앤드 캄파니-콘. 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
GB2573133A (en) 2018-04-25 2019-10-30 Ge Healthcare Bioprocess R&D Ab Separation matrix and method of separation
CN108949702A (zh) * 2018-08-01 2018-12-07 苏州纳微科技股份有限公司 超大孔径层析介质在纯化病毒颗粒的应用
GB201820806D0 (en) * 2018-12-20 2019-02-06 Ge Healthcare Bioprocess R&D Ab Large pore agarose
CN115326937B (zh) * 2021-05-11 2024-06-18 山东省食品药品检验研究院 一种基因毒杂质捕捉用固相探针及其使用方法与应用
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
CN116768985B (zh) * 2022-12-07 2024-03-22 华北制药金坦生物技术股份有限公司 一种有效纯化病毒样颗粒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP0847442A1 (en) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
CZ20012428A3 (cs) * 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic

Also Published As

Publication number Publication date
US20030170710A1 (en) 2003-09-11
EP1141249A1 (fr) 2001-10-10
KR20020044106A (ko) 2002-06-14
IL143381A (en) 2006-08-01
CZ20012428A3 (cs) 2001-11-14
NO20013271D0 (no) 2001-06-29
AU3049300A (en) 2000-07-24
AU779267B2 (en) 2005-01-13
PL349074A1 (en) 2002-07-01
KR100762033B1 (ko) 2007-10-04
BR9916654A (pt) 2002-01-15
CN1195057C (zh) 2005-03-30
HUP0104794A3 (en) 2006-03-28
CA2356373A1 (fr) 2000-07-13
NZ512504A (en) 2004-01-30
CN1332796A (zh) 2002-01-23
NO20013271L (no) 2001-08-28
US6537793B2 (en) 2003-03-25
US20020037565A1 (en) 2002-03-28
WO2000040702A1 (fr) 2000-07-13
IL143381A0 (en) 2002-04-21
JP2003523169A (ja) 2003-08-05

Similar Documents

Publication Publication Date Title
HUP0104794A2 (hu) Eljárás vírusrészecskék elkülönítésére
Rolfe et al. The relative homogeneity of microbial DNA
DE69434942D1 (de) Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
ATE85713T1 (de) Digitalprozessorsteuerung.
EP0942357A3 (en) Data processor compatible with a plurality of instruction formats
AU7101200A (en) Local register instruction for micro engine used in multithreaded parallel processor architecture
DE69733721D1 (de) Verbesserungen von screeningsverfahren für papillomviren
GB2330655A (en) Method and system for performing a binding assay
ATE281647T1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
EP1291055A3 (en) Sample processing method using ion exchange resin
ATE51876T1 (de) Monoklonale antikoerper gegen kernproteine von lymphadenopathie-assoziierten viren.
DE69933121D1 (de) Methode, reagent und testsatz zur typisierung des genoms von papillomavirus
YU71195A (sh) Prečišćeni proteini papilomavirusa
CA2199835A1 (en) Method for preparing nucleic acids for analysis and kits useful therefor
CA2319246A1 (en) Lane tracking system and method
AU9372698A (en) An (in vitro) activity assay for human hepatits b virus (hbv) dna polymerase, the use of such an assay to assay activity of various serum samples and to screen for inhibitors of the hbv dna polymerase and a method of producing hbv dna polymerase
Pantelouris et al. Genetic variation in the eel. III. Comparisons of Rhode Island and Icelandic populations. Implications for the Atlantic eel problem
DK232187A (da) Fremgangsmaade og apparat til detektion af virale dna og rna genomer i biologiske medier, navnlig i blodserum
DE50107569D1 (de) Nachweis von humanen papillomviren
ATE294237T1 (de) S?ugetier thymokingene
DE69632826D1 (de) Nukleinsaeure erkennung von hepatitis gb virus
DK0744025T3 (da) Kromatografimateriale
TR199902757T2 (xx) Grup O HIV-1 vir�slerine ba�l� enfeksiyonlar�n tespiti i�in biyolojik testlerde kullan�labilen sentetik peptitler.
HUP0105074A2 (hu) Eljárás és készülék konverter védelmére
EP0926246A3 (en) Methods of screening for modulators of respiratory syncytial virus matrix protein interaction

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees